Cargando…

Dynamic changes of Receptor activator of nuclear factor-κB expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer

Receptor-activator of nuclear-factor –κB-ligand (RANKL) and its receptor RANK have been recently identified as key players in breast cancer bone metastases. Since Circulating Tumor Cells (CTCs) are considered a crucial step of metastatic process, we explored RANK expression on CTCs in metastatic bre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pantano, Francesco, Rossi, Elisabetta, Iuliani, Michele, Facchinetti, Antonella, Simonetti, Sonia, Ribelli, Giulia, Zoccoli, Alice, Vincenzi, Bruno, Tonini, Giuseppe, Zamarchi, Rita, Santini, Daniele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987166/ https://www.ncbi.nlm.nih.gov/pubmed/31992773 http://dx.doi.org/10.1038/s41598-020-58339-2

Ejemplares similares

Osteoblasts Promote Prostate Cancer Cell Proliferation Through Androgen Receptor Independent Mechanisms
por: Ribelli, Giulia, et al.
Publicado: (2021)

Current and Emerging Biomarkers Predicting Bone Metastasis Development
por: Iuliani, Michele, et al.
Publicado: (2020)

Osteoblast Secretome Modulated by Abiraterone Treatment Affects Castration Resistant Prostate Cancer Cell Proliferation
por: Iuliani, Michele, et al.
Publicado: (2022)

Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma
por: Iuliani, Michele, et al.
Publicado: (2021)

Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment
por: Iuliani, Michele, et al.
Publicado: (2022)

Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence
por: Santini, Daniele, et al.
Publicado: (2015)

Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples
por: Russano, Marco, et al.
Publicado: (2020)

Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma
por: Simonetti, Sonia, et al.
Publicado: (2022)

Correction to: Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples
por: Russano, Marco, et al.
Publicado: (2020)

MicroRNAs and Bone Metastasis: A New Challenge
por: Croset, Martine, et al.
Publicado: (2014)

Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment
por: Iuliani, Michele, et al.
Publicado: (2015)

Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw
por: Vincenzi, Bruno, et al.
Publicado: (2012)

Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions
por: Fioramonti, Marco, et al.
Publicado: (2017)

Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment
por: Fioramonti, M., et al.
Publicado: (2018)

Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions
por: Pantano, Francesco, et al.
Publicado: (2021)

Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer Patients
por: Pantano, Francesco, et al.
Publicado: (2022)

Classification of M1/M2-polarized human macrophages by label-free hyperspectral reflectance confocal microscopy and multivariate analysis
por: Bertani, Francesca R., et al.
Publicado: (2017)

A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients
por: Rossi, Elisabetta, et al.
Publicado: (2021)

Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis
por: Pantano, Francesco, et al.
Publicado: (2022)

Detection and Prognostic Relevance of Circulating and Disseminated Tumour Cell in Dogs with Metastatic Mammary Carcinoma: A Pilot Study
por: Marconato, Laura, et al.
Publicado: (2019)

Baseline CD44v6-positive circulating tumor cells to predict first-line treatment failure in patients with metastatic colorectal cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2020)

Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor
por: Bonvini, Paolo, et al.
Publicado: (2021)

Targeting bone metastases starting from the preneoplastic niche: home sweet home
por: Santini, Daniele, et al.
Publicado: (2011)

Single-Cell Analysis of Circulating Tumor Cells: How Far Have We Come in the -Omics Era?
por: Rossi, Elisabetta, et al.
Publicado: (2019)

First-line targeted therapies in the treatment of metastatic colorectal cancer – role of cetuximab
por: Tonini, Giuseppe, et al.
Publicado: (2009)

Possible role of circulating tumor cells in early detection of lung cancer
por: Poggiana, Cristina, et al.
Publicado: (2020)

Deregulation of dicer and mir-155 expression in liposarcoma
por: Vincenzi, Bruno, et al.
Publicado: (2015)

Procalcitonin as diagnostic marker of infection in solid tumors patients with fever
por: Vincenzi, B., et al.
Publicado: (2016)

Clinical significance of circulating tumor cells and cell‐free DNA in pediatric rhabdomyosarcoma
por: Tombolan, Lucia, et al.
Publicado: (2022)

Retaining the long-survive capacity of Circulating Tumor Cells (CTCs) followed by xeno-transplantation: not only from metastatic cancer of the breast but also of prostate cancer patients
por: Rossi, Elisabetta, et al.
Publicado: (2013)

Facing SARS-CoV-2 outbreak in immunotherapy era
por: Citarella, Fabrizio, et al.
Publicado: (2020)

Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer
por: Tonini, Giuseppe, et al.
Publicado: (2013)

Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer
por: Santini, Daniele, et al.
Publicado: (2006)

Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma
por: Vincenzi, Bruno, et al.
Publicado: (2017)

Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview
por: Argentiero, Antonella, et al.
Publicado: (2019)

Clinical relevance of the combined analysis of circulating tumor cells and anti-tumor T-cell immunity in metastatic breast cancer patients
por: Muraro, Elena, et al.
Publicado: (2022)

Liquid Biopsy in Pediatric Renal Cancer: Stage I and Stage IV Cases Compared
por: Rossi, Elisabetta, et al.
Publicado: (2020)

Dysmetabolic Circulating Tumor Cells Are Prognostic in Metastatic Breast Cancer
por: Brisotto, Giulia, et al.
Publicado: (2020)

Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib
por: Manca, Paolo, et al.
Publicado: (2017)

Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancer
por: Suriano, Francesca, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_eerbl9paghdtas15q30dp7l4i1